Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults.

Trial Profile

Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2009

At a glance

  • Drugs West Nile virus vaccine (Primary) ; Aluminium hydroxide
  • Indications West Nile virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2009 Results reported in a Hawaii Biotech media release.
    • 16 Dec 2008 Preliminary safety results and immunologic data will be available early in 2009; complete results are expected by the third quarter 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top